Skip to content 
Competitor portfolio and strategy benchmarking in rare diseases market
Impact
0%
Reduction in time-to-market compared to their usual development cycle.
0%
Market share captured in the rare disease segment within the first year by addressing a critical treatment gap in the market.
Positioned the client as an innovator in the rare disease market, opening new opportunities for collaborations with academic institutions and biotechnology firms.
DOWNLOAD:
Client
Leading pharma company specializing in chronic and rare diseases
Products
Innovative drugs for rare and underserved diseases
Industries
Pharmaceuticals
target geo
Global
business objective
- The client aimed to expand their presence in the rare disease market but faced challenges identifying potential therapeutic areas with unmet needs. Competitors had already established significant pipelines in certain rare diseases, making it critical to uncover white spaces for innovation and establishing market leadership.
- The objective was to benchmark competitors’ drug portfolios, analyze their pipelines, and identify underserved therapeutic areas to guide the launch of a new orphan drug.
Our solution
- Product Portfolio Analysis: Conducted an in-depth benchmarking of competitors’ portfolios, focusing on drugs under development and those already launched for rare diseases; Mapped therapeutic areas with high saturation and identified diseases with limited or no treatment options; Assessed the clinical efficacy, innovation level, and market performance of competitors’ drugs to pinpoint gaps and untapped opportunities.
- Pipeline and Clinical Trial Assessment: Analyzed competitors’ drug development pipelines to identify key stages of clinical trials, geographical focus, and potential launch timelines; Examined therapeutic areas where clinical trial activity was minimal or non-existent, flagging opportunities for first-mover advantage.
- Market Demand and Feasibility Analysis: Conducted a Voice of the Customer study with 10 industry stakeholders, including medical researchers, regulatory advisors, and key opinion leaders; Gained insights into market demand for orphan drugs and uncovered patient demographics with unmet needs; Developed a white space roadmap highlighting priority therapeutic areas and identified potential partner research organizations and biotechnology firms to fast-track R&D.
Outcome
- The client launched a new orphan drug targeting a rare neurological disorder, reducing time-to-market by 10% compared to their usual development cycle.
- Captured 6% market share in the rare disease segment within the first year by addressing a critical treatment gap in the market.
- Positioned the client as an innovator in the rare disease market, opening new opportunities for collaborations with academic institutions and biotechnology firms.
Related Stories
Ready to Explore How Cognition Can Grow Your Business?
Hi, This is Emma. Let’s get the conversation started!